Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

469 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system.
Sabathé C, Casey R, Vukusic S, Leray E, Mathey G, De Sèze J, Ciron J, Wiertlewski S, Ruet A, Pelletier J, Zéphir H, Michel L, Lebrun-Frenay C, Moisset X, Thouvenot E, Camdessanché JP, Bakchine S, Stankoff B, Al Khedr A, Cabre P, Maillart E, Berger E, Heinzlef O, Hankiewicz K, Moreau T, Gout O, Bourre B, Wahab A, Labauge P, Montcuquet A, Defer G, Maurousset A, Maubeuge N, Dimitri Boulos D, Ben Nasr H, Nifle C, Casez O, Laplaud DA, Foucher Y. Sabathé C, et al. Among authors: labauge p. Mult Scler. 2023 Feb;29(2):236-247. doi: 10.1177/13524585221139156. Epub 2022 Dec 14. Mult Scler. 2023. PMID: 36515394
Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort study.
Wilson S, Calocer F, Rollot F, Fauvernier M, Remontet L, Tron L, Vukusic S, Le Page E, Debouverie M, Ciron J, Ruet A, De Sèze J, Zephir H, Moreau T, Lebrun-Frénay C, Laplaud DA, Clavelou P, Labauge P, Berger E, Pelletier J, Heinzlef O, Thouvenot E, Camdessanché JP, Leray E, Dejardin O, Defer G. Wilson S, et al. Among authors: labauge p. Lancet Reg Health Eur. 2022 Nov 17;24:100542. doi: 10.1016/j.lanepe.2022.100542. eCollection 2023 Jan. Lancet Reg Health Eur. 2022. PMID: 36426377 Free PMC article.
Pregnancy and post-partum in patients with myelin-oligodendrocyte glycoprotein antibody-associated disease.
Carra-Dallière C, Rollot F, Deschamps R, Ciron J, Vukusic S, Audoin B, Ruet A, Maillart E, Papeix C, Zephir H, Laplaud D, Cohen M, Bourre B, El-Bahi I, Labauge P, Casey R, Ayrignac X, Marignier R. Carra-Dallière C, et al. Among authors: labauge p. Mult Scler. 2023 Feb;29(2):270-276. doi: 10.1177/13524585221134214. Epub 2022 Dec 1. Mult Scler. 2023. PMID: 36453174
The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus.
De Sèze J, Suchet L, Mekies C, Manchon E, Labauge P, Guennoc AM, Defer G, Clavelou P, Castelnovo G, Bourre B, Bensa-Koscher C, Al Khedr A, Le Mao J, Villemur L, Bouée S, Luciani L, Vermersch P. De Sèze J, et al. Among authors: labauge p. Neurol Ther. 2023 Apr;12(2):351-369. doi: 10.1007/s40120-022-00430-z. Epub 2022 Dec 24. Neurol Ther. 2023. PMID: 36564664 Free PMC article. Review.
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis.
Garcia A, Dugast E, Shah S, Morille J, Lebrun-Frenay C, Thouvenot E, De Sèze J, Le Page E, Vukusic S, Maurousset A, Berger E, Casez O, Labauge P, Ruet A, Raposo C, Bakdache F, Buffels R, Le Frère F, Nicot A, Wiertlewski S, Gourraud PA, Berthelot L, Laplaud D. Garcia A, et al. Among authors: labauge p. Neurol Neuroimmunol Neuroinflamm. 2023 Feb 21;10(3):e200091. doi: 10.1212/NXI.0000000000200091. Print 2023 May. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 36810163 Free PMC article.
Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis.
Januel E, Hajage D, Labauge P, Maillart E, De Sèze J, Zephir H, Pelletier J, Guilloton L, Bensa C, Heinzlef O, Casez O, Biotti D, Bourre B, Vukusic S, Maurousset A, Berger E, Laplaud D, Lebrun-Frénay C, Dubessy AL, Branger P, Thouvenot E, Clavelou P, Sellal F, Manchon E, Moreau T, Papeix C, Tubach F, Louapre C. Januel E, et al. Among authors: labauge p. JAMA Netw Open. 2023 Jun 1;6(6):e2319766. doi: 10.1001/jamanetworkopen.2023.19766. JAMA Netw Open. 2023. PMID: 37351881 Free PMC article.
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.
Lorscheider J, Signori A, Subramaniam S, Benkert P, Vukusic S, Trojano M, Hillert J, Glaser A, Hyde R, Spelman T, Magyari M, Elberling F, Pontieri L, Koch-Henriksen N, Sørensen PS, Gerlach O, Prat A, Girard M, Eichau S, Grammond P, Horakova D, Ramo-Tello C, Roos I, Buzzard K, Lechner Scott J, Sánchez-Menoyo JL, Alroughani R, Prévost J, Kuhle J, Gray O, Mathey G, Michel L, Ciron J, De Sèze J, Maillart E, Ruet A, Labauge P, Zephir H, Kwiatkowski A, van der Walt A, Kalincik T, Butzkueven H; Italian MS Register; Observatoire Français de la Sclérose en Plaques (OFSEP); MSBase Study Group; Swedish MS Registry; Big MS Data Network. Lorscheider J, et al. Among authors: labauge p. J Neurol Neurosurg Psychiatry. 2024 Dec 6:jnnp-2024-334700. doi: 10.1136/jnnp-2024-334700. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 39643429 Free article.
Association between education level and access to disease-modifying treatment in patients with multiple sclerosis in France.
Lefort M, Dejardin O, Berger E, Camdessanché JP, Ciron J, Clavelou P, De Sèze J, Debouverie M, Heinzlef O, Labauge P, Laplaud DA, Michel L, Lebrun-Frénay C, Moreau T, Pelletier J, Ruet A, Thouvenot E, Vukusic S, Zephir H, Defer G, Leray E. Lefort M, et al. Among authors: labauge p. Mult Scler. 2024 Dec 1:13524585241289276. doi: 10.1177/13524585241289276. Online ahead of print. Mult Scler. 2024. PMID: 39618051
469 results